299 related articles for article (PubMed ID: 28138028)
1. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
Zeng L; Beggs RR; Cooper TS; Weaver AN; Yang ES
Mol Cancer Ther; 2017 Apr; 16(4):591-600. PubMed ID: 28138028
[TBL] [Abstract][Full Text] [Related]
2. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
[TBL] [Abstract][Full Text] [Related]
3. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ
Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
5. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
6. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
7. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma.
Chaudhary R; Slebos RJC; Song F; McCleary-Sharpe KP; Masannat J; Tan AC; Wang X; Amaladas N; Wu W; Hall GE; Conejo-Garcia JR; Hernandez-Prera JC; Chung CH
Mol Carcinog; 2021 Feb; 60(2):138-150. PubMed ID: 33378592
[TBL] [Abstract][Full Text] [Related]
8. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
9. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
10. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma.
Guy JB; Espenel S; Louati S; Gauthier A; Garcia MA; Vial N; Malésys C; Ardail D; Alphonse G; Wozny AS; Rodriguez-Lafrasse C; Magné N
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1905-1916. PubMed ID: 33791846
[TBL] [Abstract][Full Text] [Related]
11. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
12.
Gadhikar MA; Zhang J; Shen L; Rao X; Wang J; Zhao M; Kalu NN; Johnson FM; Byers LA; Heymach J; Hittelman WN; Udayakumar D; Pandita RK; Pandita TK; Pickering CR; Redwood AB; Piwnica-Worms H; Schlacher K; Frederick MJ; Myers JN
Cancer Res; 2018 Feb; 78(3):781-797. PubMed ID: 29229598
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
[TBL] [Abstract][Full Text] [Related]
17. EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models.
Koi L; Löck S; Linge A; Thurow C; Hering S; Baumann M; Krause M; Gurtner K
Radiother Oncol; 2017 Sep; 124(3):496-503. PubMed ID: 28807520
[TBL] [Abstract][Full Text] [Related]
18. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
[TBL] [Abstract][Full Text] [Related]
19. The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines.
Güster JD; Weissleder SV; Busch CJ; Kriegs M; Petersen C; Knecht R; Dikomey E; Rieckmann T
Radiother Oncol; 2014 Dec; 113(3):345-51. PubMed ID: 25467050
[TBL] [Abstract][Full Text] [Related]
20. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
